Cognition Therapeutics Granted Extension for Compliance with Nasdaq Listing Requirements Amid Struggles in Share Price
PURCHASE, N.Y. March 12, 2025 Cognition Therapeutics, Inc.(Nasdaq: CGTX), a clinical-stage biotech company focused on innovative treatments for neurodegenerative disorders, received a crucial extension from the Nasdaq Stock Market.This decision, communicated on March 11, 2025, gives the company additional time to meet the necessary bid price requirements for continued listing.
The background to this development is critical for understanding Cognition s current market position.On September 12, 2024, the company was notified that its common stock had traded below the $1.00 threshold for 30 consecutive business days.In response, Nasdaq granted Cognition a 180-day grace period to return to compliance by achieving a closing price of at least $1.00 for ten consecutive days.
As of the closing date of the compliance period on March 11, 2025, Cognition Therapeutics’ stock was priced at $0.4401, significantly below the required threshold.With approximately 40.4 million shares outstanding, the current market capitalization reflects investor concerns regarding the company’s financial stability and growth potential.
It is essential to contextualize this extension within the broader narrative of Cognition’s clinical trials and product development.Just months prior, the company garnered attention for its research advances, including a press release dated December 18, 2024
Comments